ArticleBMC musculoskeletal disorders2025
FGA can be used as a promising therapeutic target in osteoarthritis.
Article in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Omics Studies in Osteoarthritis: A Review of Molecular Mechanisms and Candidate Molecules.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThis study aims to identify critical signaling pathways and pathogenic genes involved in osteoarthritis (OA) to provide a foundation for identifying targeted therapeutic strategies.
methodsTwenty-six patients who underwent knee joint surgery in the Department of Orthopedics between January and December 2023 were enrolled. Cartilage samples in the experimental group (OA group) were harvested from the articular surfaces of the knee joints of OA patients undergoing total knee arthroplasty (TKA). In contrast, control samples were obtained from non-load-bearing regions of irreparable cartilage fragments excised during surgical management of tibial plateau fractures. Proteomic profiling was conducted using label-free quantitative mass spectrometry-based proteomics. Subsequent bioinformatics analysis was performed using R version 4.3.3 to identify differentially expressed proteins and key pathogenic genes. Quantitative real-time polymerase chain reaction (qPCR) and western blots were employed to validate the expression levels of candidate genes.
resultsThe proteomic analysis revealed that regulatory signaling pathway of insulin-like growth factor-binding protein (IGFBP) for IGF transport and uptake and the platelet degranulation signaling pathway were significantly implicated in OA pathogenesis. Among the differentially expressed proteins, fibrinogen alpha chain (FGA) was identified as a central gene associated with OA. The qPCR and western blots validation confirmed significantly elevated expression of FGA in OA articular chondrocytes samples compared to controls.
conclusionsFGA plays a pivotal role in the molecular pathology of OA and may represent a promising therapeutic target for the development of precision treatments for OA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.